Company: IPODW
Filing Date: 2025-03-07
Form Type: S-1
Source: 0001213900-25-021721
Chunk: 163

Company: Dune Acquisition Corp II
Filing Date: 2025-03-07
Form: S-1
Chunk 163
---
,250,000 | )         |     |   |  (12,937,500 | )         |     |             |  (15,000,000 | )         |     |   |  (17,250,000 | ) |
|                                                                                                    |     |                |  21,112,500 |           |     |   |  24,279,375 |           |     |                |  17,362,500 |           |     |   |  19,966,875 |           |     |                |  13,612,500 |           |     |   |  15,654,375 |           |     |                |    9,862,500 |           |     |   |   11,314,875 |           |     |             |    6,112,500 |           |     |   |    7,029,375 |   |

____________ (1)Expenses applied against gross proceeds include offering expenses of approximately $ 500 ,000 (excluding deferred underwriting commissions). See “ Use of Proceeds .” (2)Upon the consummation of our initial business combination, the deferred underwriting commissions would be paid as follows: (A) $ 00.05 per unit sold in the offering, or $ 750,000 in the aggregate, is payable upon the closing of this offering (or $ 862,500 if the over -allotment option is exercised in full); and (B) up to $0.40 per unit, or up to $6,000,000 (or up to $6,900,000 if the underwriters’ over -allotment option is exercised in full) in the aggregate, payable to the underwriters for deferred underwriting commissions to be placed in a trust account located in the United States as described herein. See also “Underwriting” for additional information regarding underwriting compensation.

108

CAPITALIZATION The following table sets forth our capitalization at December31, 2024, and as adjusted to give effect to the filing of our amended and restated memorandum and articles of association, the sale of our units in this offering and the sale of the private placement warrants and the application of the estimated net proceeds derived from the sale of such securities, assuming no exercise by the underwriters of their over -allotmentoption:

|                                                                                                                                                                              |     | December 31, 2024 |         |   |     |